Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy

Acta Gastro-Enterologica Belgica

Volumn 70, Issue 1, 2007, Pages 20-24

  Akyuz, Filiz ^a,b   Kaymakoglu, Sabahattin ^a   Demir, Kadir ^a   Aksoy, Nevzat ^a   Karaca, Cetin ^a   Danalioglu, Ahmet ^a   Onel, Derya ^a   Badur, Selim ^a   Besisik, Fatih ^a   Cakaloglu, Yilmaz ^a   Okten, Atilla ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

HBeAg negative chronic hepatitis B; Interferon non responder; YMDD mutations

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA2B INTERFERON; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; MALE; MONOTHERAPY; MUTATIONAL ANALYSIS; PROTEIN MOTIF;

ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION;

EID: 34247105858     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. OKTEN A., DEMIR K., KAYMAKOGLU S., CAKALOGLU Y., DINCER D., BESISIK F. Etiologies of chronic hepatitis. Turkish J. Gastroenterol., 1998, 2 : 113-115.
2. WAI C.T., LOK A.S.F. Treatment of hepatitis Br. J. Gastroenterol., 2002, 37 : 771-778.
3. PAPATHEODORIDIS G.V., MANESIS E., HADZIYANNIS S.J. The long term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis Br. J. Hepatol., 2001, 34 : 306-313.
4. SANTANTONIO T., MAZZOLA M., IACOVAZZI T., MIGLIETTA A., GUASTADISEGNI A., PASTORE G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J. Hepatol., 2000, 32 : 300-306.
5. RIZZETTO M., VOLPES R., SMEDILE A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. J. Med. Virol., 2000, 61: 398-400.
6. DIENSTAG J.L., GOLDIN R.D., HEATHCOTE E.J., HANN H.W., WOESSNER M., STEPHENSON S.L., GARDNER S., GRAY D.F., SCHIFF E.R. Histological outcome during long-term lamivudine therapy. Gastroenterology, 2003, 124 : 105-117.
7. HADZIYANNIS S.J. Treatment options for chronic hepatitis B not responding to interferon. J. Hepatol., 2003, 38 : 853-855.
8. KNODELL R.G., ISHAK K.G., BLACK W.C., CHEN T.S., CRAIG R., KAPLOWITZ N., KIERNAN T.W., WOLLMAN J. Formulation and application of a numerical scoring system for assessing histological activity in asempthomatic chronic active hepatitis. Hepatology, 1981, 1 : 431-435.
9. KWOK S., HIGUCHI R. Avoiding false positives with PCR. Nature, 1989, 339 : 237-238.
10. BOOM R., SOL C.J., SALIMANS M.M., JANSEN C.L., WERTHEIM-VAN DILLEN P.M., VANDER NOORDAA J. Rapid and simple method for purification of nucleic acid. J. Clin. Microbiol., 1990, 28 : 495-503.
11. BOOM R., SOL C.J., HEIJTINK R., WERTHEIM-VAN DILLEN P.M., VANDER NOORDAA J. Rapid purification of hepatitis B virus DNA from serum. J. Clin. Microbiol., 1991, 29 : 1804-1811.
12. HADZIYANNIS S.J., VASSILOPOULOS D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology, 2001, 34 : 617-624.
13. PAPATHEODORIDIS G.V., HADZIYANNIS S.J. Diagnosis and management of pre-core mutant chronic hepatitis B. J. Viral Hepatol., 2001, 8 : 311-321.
14. LOK A.S.F., MC MAHON B.J. Chronic hepatitis B. Hepatology, 2001, 34 : 1225-1241.
15. HADZIYANNIS S.J., PAPATHEODORIDIS G.V., VASSILOPOULOS D. Treatment of HBeAg-negative chronic hepatitis B. Sem. in Liver Dis., 2003, 23 : 81-88.
16. BRUNETTO M.R., OLIVERI F., COLOMBATO P., CAPALBO M., BARBERA C., BONINO F. Treatment of chronic anti-HBe-positive hepatitis B with interferon-alpha. J. Hepatol., 1995, 22 : 42-44.
17. OLIVERI F., SANTANTONIO T., BELLATI G., COLOMBATTO P., MELS G.C., CARRIERO L., DASTOLI G., PASTORE G., IDEO G., BONINO F., BRUNETTO M.R. Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. Am. J. Gastroenterol., 1999, 94 : 1366-1372.
18. VERSCHUERE V., YAP P.S., FEVERY J. Is HBV genotyping of clinical relevance ? Acta Gastroenterol. Belg., 2005, 68 : 233-6.
19. ADLER M., GOUBAU P., LEROUX-ROELS G., SPRENGERS D., PAWLOTSKY J.M. Practical use of hepatitis C and B molecular tools : Belgian guidelines. Acta Gastroenterol. Belg., 2005, 68 : 308-13
20. HADZIYANNIS S., PAPATHEODORIDIS G., DIMOU E., LARAS A., PAPAIOANNOU C. Efficacy of long-term lamivudine monotherapy in patients with HBeAg-negative chronic hepatitis B. Hepatology, 2000, 32 : 847-851.
21. TATULLI I., FRANCAVILLA R., RIZZO G.L., VINCIGVERRA V., IERARDI E., AMORUSO A., PANELLA C., FRANCAVILLA A. Lamivudine and alpha interferon in combination long term precore mutant chronic hepatitis B. J. Hepatol., 2001, 35 : 805-810.
22. KAPLAN D.E., REDDY K.R. One two tandem of lamivudine and interferon might work for patients with chronic hepatitis B who failed interferon monotherapy. Am. J. Gastroenterol., 2002, 97 : 2463-2467.
23. SERFATY L., THABUT D., ZOULIM F., ANDREANI T., CHAZOILLERES O., CARBONELL N., LORIA A., POUPON R. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone : Results of a pilot study. Hepatology, 2001, 34 : 573-577.
24. MANESIS E.K., HADZIYANNIS S.J. Interferon-alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology, 2001, 12 : 91-100.
25. YANG S.S., HSU C.T., HU J.T., LAI Y.C., WU C.H. Lamivudine does not increase the efficacy of interferon in the treatment of mutant type chronic viral hepatitis B. World J. Gastroenterol., 2002, 8 : 868-871.
26. MUTIMER D., NAOUMOV N., HONCOOP P., MARINOS G., AHMED M., DE MAN R., MC PHILLIPS P., JOHNSON M., WILLIAMS R., ELIAS E. Combination alpha-interferon lamivudine therapy for chronic hepatitis B infection : Results of a pilot study. J. Hepatol., 1998, 28 : 923-929.
27. SCHIFF E.R., DIENSTAG J.L., KARAYALCIN S., GRIMM I.S., PERRILLO R.P., HUSA P., DE MAN R.A., GOODMAN Z., CONDREAY L.D., CROWTHER L.M., WOESSNER M.A., MC PHILLIPS P.J., BROWN N.A., INTERNATIONAL LAMIVUDINE INVESTIGATOR GROUP. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J. Hepatol., 2003, 38 : 818-826.
28. BUTI M., COTRINA M., JORDI R., DE CASTRO E.C., RODRIGEZ-FRIAS F., SANCHEZ-AVILA F., ESTEBAN R., GUARDIA J. Two years of lamivudine therapy in anti-HHe-positive patients with chronic hepatitis B. J. Viral. Hepatol., 2001, 8 : 270.
29. SANTANTONIO T., NIRO G.A., SINISI E., LEANDRO G., INSALATA M., GUASTADISEGNI A., FACCIORUSSO D., GRAVINESE E., ANDRIULLI A., PASTORE G. Lamivudine/interferon combination therapy in antiHBe positive chronic hepatitis B patients : a controlled pilot study. J. Hepatol., 2002, 36 : 799-802.